Artelo Biosciences Inc

NASDAQ:ARTL  
0.34
+0.01 (+2.36%)
Earnings Announcements

Artelo Biosciences Reports First Quarter 2022 Financial Results

Published: 05/12/2022 12:40 GMT
Artelo Biosciences Inc (ARTL) - Artelo Biosciences Reports First Quarter 2022 Financial Results and Provides Business Update.
Q1 Loss per Share $0.05.
Results of Phase 1b Cares Trial Anticipated in Q3 2022.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.07

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.08

More details on our Analysts Page.